The U.S. Food and Drug Administration (FDA) granted initial approval for a generic version of dapagliflozin on April 6, 2026. This approval, documented under Abbreviated New Drug Application (ANDA) 211482, was issued to AJANTA PHARMA LTD., signifying the availability of the first generic form of this important medication.
Background
Dapagliflozin is an established oral medication, also known by its brand name Farxiga, which is listed among its aliases. The reference listed drug, for which this generic is approved, has established indications including improving glycemic control in adults with type 2 diabetes mellitus, reducing the risk of cardiovascular death and hospitalization for heart failure, and reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease.
What this means
The initial FDA approval of a generic version of dapagliflozin by AJANTA PHARMA LTD. represents a significant milestone in expanding access to this therapeutic agent. Generic medications are bioequivalent to their brand-name counterparts and are typically introduced at lower costs, which can lead to increased affordability and broader patient access for conditions such as type 2 diabetes mellitus, heart failure, and chronic kidney disease. This development is expected to foster a more competitive market for dapagliflozin, potentially benefiting healthcare systems and patients by offering more economical treatment options.
Source
The information regarding this initial approval was officially released by the U.S. Food and Drug Administration (FDA). The approval for Abbreviated New Drug Application (ANDA) 211482, sponsored by AJANTA PHARMA LTD., was recorded on April 6, 2026. Further details are available on the FDA's accessdata.fda.gov website, which serves as the authoritative source for this regulatory action.